Plain-English translation of NCT07192185 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a combination of chemotherapy (called ) plus atezolizumab and bevacizumab can help people with advanced liver cancer whose disease has progressed after they already received atezolizumab and bevacizumab as a first-line treatment. The goal is to see if adding chemotherapy to these two medications makes the treatment more effective and safe for patients who have not responded well to the initial combination.
When people with advanced liver cancer receive atezolizumab and bevacizumab as their first treatment, the cancer sometimes continues to grow or come back. Doctors don't yet have a clear best option for what to do next, so this trial is investigating whether adding chemotherapy to the same two medications might work better as a second-line approach.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive the three-medication combination ( chemotherapy plus atezolizumab and bevacizumab) as your treatment. While the trial description does not specify exact visit schedules or duration, you can expect regular clinic visits for treatment administration, blood tests to monitor how you are tolerating the medication, and imaging scans to check how your cancer is responding. The trial is enrolling 30 patients total.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China